Detection of cancer specific mutations in early-stage non-small cell lung cancer using cell-free DNA by targeted sequencing

He,Yutong; Zhang,Xinyuan; Wang,Liqun; Tian,Ziqiang; Liu,Qingyi; Yao,Jifang; Liu,Yueping; Li,Chuanbao; Min,Li; Shan,Baoen

doi:10.3892/ijo.2016.3731

Detection of cancer specific mutations in early-stage non-small cell lung cancer using cell-free DNA by targeted sequencing

Authors:
- Yutong He
- Xinyuan Zhang
- Liqun Wang
- Ziqiang Tian
- Qingyi Liu
- Jifang Yao
- Yueping Liu
- Chuanbao Li
- Li Min
- Baoen Shan
View Affiliations

Affiliations: The Fourth Hospital of Hebei Medical University/The Tumor Hospital of Hebei Province, Shijiazhuang, Hebei 050011, P.R. China, Institute of Genecrab Precision Medicine, Beijing 100078, P.R. China, Department of Clinical Laboratory, Beijing Hospital, Beijing 100730, P.R. China, Department of Biochemistry and Molecular Biology, Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China
Published online on: October 12, 2016 https://doi.org/10.3892/ijo.2016.3731
Pages: 2351-2358

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non-small cell lung cancer (NSCLC) is a major public health problem worldwide and leads to a high mortality. NSCLC is always diagnosed in late stages because of its unapparent symptoms. However, cell-free DNA (cfDNA) may serve as a new potential biomarker to detect early stage of non‑small cell lung cancer. Here we recruited 10 non-small cell lung cancer patients to obtain fresh tumor tissue, peripheral blood lymphocytes (PBLs), and plasma. CfDNAs from 13 elderly people and 7 middle-age smokers were also extracted as controls. Illumina HiSeq X10 was used to perform next-generation sequencing to evaluate differences in mutations among different samples. The result indicated that tumor DNA and its matched plasma cfDNA samples showed high concordance in their mutation patterns. Mutation rate of cfDNA was generally lower than that of tumor tissue and higher than that of PBLs. The plasma cfDNA concentration of NSCLC patients (69.2±46.9 ng/ml) is significantly higher than that of elderly people (32.5±5.2 ng/ml, t=2.96, p=0.007) and middle-aged smokers (17.9±9.1 ng/ml, t=2.83, p=0.013). Five mutations (PTEN_c.1375A>G, TP53_c.94G>A, STK11_c.816C>T, PIK3CA_c.1633 G>A, PIK3CA_c.2038G>C) were only identified in NSCLC patients but not in healthy people. Our conclusion was that cfDNA has a similar mutation pattern with its matched tumor tissue DNA. A high concentration of cfDNA and tumor specific mutations in cfDNA may serve as potential non-invasive biomarkers to detect early-stage non‑small cell lung cancer.

View Figures

View References

1	Catarino R, Coelho A and Medeiros R: Circulating DNA and NSCLC: Old findings with new perspectives. J Thorac Dis. 4:442–443. 2012.PubMed/NCBI
2	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
3	Islami F, Torre LA and Jemal A: Global trends of lung cancer mortality and smoking prevalence. Transl Lung Cancer Res. 4:327–338. 2015.PubMed/NCBI
4	Torre LA, Siegel RL, Ward EM and Jemal A: International variation in lung cancer mortality rates and trends among women. Cancer Epidemiol Biomarkers Prev. 23:1025–1036. 2014. View Article : Google Scholar : PubMed/NCBI
5	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
6	Reade CA and Ganti AK: EGFR targeted therapy in non-small cell lung cancer: Potential role of cetuximab. Biologics. 3:215–224. 2009.PubMed/NCBI
7	Agarwal M, Brahmanday G, Chmielewski GW, Welsh RJ and Ravikrishnan KP: Age, tumor size, type of surgery, and gender predict survival in early stage (stage I and II) non-small cell lung cancer after surgical resection. Lung Cancer. 68:398–402. 2010. View Article : Google Scholar
8	Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM and Sicks JD; National Lung Screening Trial Research Team: Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 365:395–409. 2011. View Article : Google Scholar : PubMed/NCBI
9	Church TR, Black WC, Aberle DR, Berg CD, Clingan KL, Duan F, Fagerstrom RM, Gareen IF, Gierada DS, Jones GC, et al; National Lung Screening Trial Research Team. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 368:1980–1991. 2013. View Article : Google Scholar : PubMed/NCBI
10	Lai Y, Shen C, Wang X, Du H, Chen D, Tian L, Zhou X and Che G: Status and perspectives of detection by low-dose computed tomography or computed radiography in surgical patients with lung cancer, based on a five-year study. Thorac Cancer. 7:111–117. 2016. View Article : Google Scholar : PubMed/NCBI
11	Zhao SJ and Wu N: Early detection of lung cancer: Low-dose computed tomography screening in China. Thorac Cancer. 6:385–389. 2015. View Article : Google Scholar : PubMed/NCBI
12	Silva M, Galeone C, Sverzellati N, Marchianò A, Calareso G, Sestini S, La Vecchia C, Sozzi G, Pelosi G and Pastorino U: Screening with low-dose computed tomography does not improve survival of small cell lung cancer. J Thorac. 11:187–193. 2016. View Article : Google Scholar
13	Tissot C, Toffart AC, Villar S, Souquet PJ, Merle P, Moro-Sibilot D, Pérol M, Zavadil J, Brambilla C, Olivier M, et al: Circulating free DNA concentration is an independent prognostic biomarker in lung cancer. Eur Respir J. 46:1773–1780. 2015. View Article : Google Scholar : PubMed/NCBI
14	Moyer VA; U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 160:330–338. 2014.PubMed/NCBI
15	Humphrey L, Deffebach M, Pappas M, et al: U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. Screening for Lung Cancer: Systematic Review to Update the US Preventive Services Task Force Recommendation. Agency for Healthcare Research and Quality (US); Rockville, MD: 2013
16	Sun W, Yuan X, Tian Y, Wu H, Xu H, Hu G and Wu K: Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer. J Hematol Oncol. 8:952015. View Article : Google Scholar : PubMed/NCBI
17	Nygaard AD, Garm Spindler KL, Pallisgaard N, Andersen RF and Jakobsen A: The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer. Lung Cancer. 79:312–317. 2013. View Article : Google Scholar
18	Guo K, Zhang Z, Han L, Han J, Wang J, Zhou Y, Liu H, Tong L, Li X and Yan X: Detection of epidermal growth factor receptor mutation in plasma as a biomarker in Chinese patients with early-stage non-small cell lung cancer. Onco Targets Ther. 8:3289–3296. 2015. View Article : Google Scholar : PubMed/NCBI
19	Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer. 94:153–156. 2001. View Article : Google Scholar : PubMed/NCBI
20	Rossi A, Maione P, Colantuoni G, Gaizo FD, Guerriero C, Nicolella D, Ferrara C and Gridelli C: Screening for lung cancer: New horizons? Crit Rev Oncol Hematol. 56:311–320. 2005. View Article : Google Scholar : PubMed/NCBI
21	Brambilla C, Fievet F, Jeanmart M, de Fraipont F, Lantuejoul S, Frappat V, Ferretti G, Brichon PY and Moro-Sibilot D: Early detection of lung cancer: Role of biomarkers. Eur Respir J. (Supplement 39): S36–S44. 2003. View Article : Google Scholar
22	Murtaza M, Dawson SJ, Pogrebniak K, Rueda OM, Provenzano E, Grant J, Chin SF, Tsui DW, Marass F, Gale D, et al: Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat Commun. 6:87602015. View Article : Google Scholar : PubMed/NCBI
23	Wu TL, Zhang D, Chia JH, Tsao K, Sun CF and Wu JT: Cell-free DNA: Measurement in various carcinomas and establishment of normal reference range. Clin Chim Acta. 321:77–87. 2002. View Article : Google Scholar : PubMed/NCBI
24	Lee YJ, Yoon K-A, Han J-Y, Kim HT, Yun T, Lee GK, Kim HY and Lee JS: Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. Clin Cancer Res. 17:5179–5187. 2011. View Article : Google Scholar : PubMed/NCBI
25	Jamal-Hanjani M, Wilson GA, Horswell S, Mitter R, Sakarya O, Constantin T, Salari R, Kirkizlar E, Sigurjonsson S, Pelham R, et al: Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer. Ann Oncol. 27:862–867. 2016. View Article : Google Scholar : PubMed/NCBI
26	Couraud S, Vaca-Paniagua F, Villar S, Oliver J, Schuster T, Blanché H, Girard N, Trédaniel J, Guilleminault L, Gervais R, et al: Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: A proof-of-concept study from BioCAST/IFCT-1002. Clin Cancer Res. 20:4613–4624. 2014. View Article : Google Scholar : PubMed/NCBI
27	Duan H, Lu J, Lu T, Gao J, Zhang J, Xu Y, Wang M, Wu H, Liang Z and Liu T: Comparison of EGFR mutation status between plasma and tumor tissue in non-small cell lung cancer using the Scorpion ARMS method and the possible prognostic significance of plasma EGFR mutation status. Int J Clin Exp Pathol. 8:13136–13145. 2015.
28	Jung K, Fleischhacker M and Rabien A: Cell-free DNA in the blood as a solid tumor biomarker - a critical appraisal of the literature. Clin Chim Acta. 411:1611–1624. 2010. View Article : Google Scholar : PubMed/NCBI
29	Shapiro B, Chakrabarty M, Cohn EM and Leon SA: Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer. 51:2116–2120. 1983. View Article : Google Scholar : PubMed/NCBI
30	Anker P and Stroun M: Circulating DNA in plasma or serum. Medicina (B Aires). 60:699–702. 2000.
31	Schwarzenbach H, Hoon DS and Pantel K: Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 11:426–437. 2011. View Article : Google Scholar : PubMed/NCBI
32	Feng J, Gang F, Li X, Jin T, Houbao H, Yu C and Guorong L: Plasma cell-free DNA and its DNA integrity as biomarker to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate-specific antigen. Int Urol Nephrol. 45:1023–1028. 2013. View Article : Google Scholar : PubMed/NCBI
33	Huang ZH, Li LH and Hua D: Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients. Cancer Lett. 243:64–70. 2006. View Article : Google Scholar : PubMed/NCBI
34	Ulivi P and Silvestrini R: Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer. Cell Oncol (Dordr). 36:439–448. 2013. View Article : Google Scholar
35	Huang R, Wei Y, Hung RJ, Liu G, Su L, Zhang R, Zong X, Zhang ZF, Morgenstern H, Brüske I, et al: Associated links among smoking, chronic obstructive pulmonary disease, and small cell lung cancer: A pooled analysis in the International Lung Cancer Consortium. EBioMedicine. 2:1677–1685. 2015. View Article : Google Scholar
36	Gormally E, Caboux E, Vineis P and Hainaut P: Circulating free DNA in plasma or serum as biomarker of carcinogenesis: Practical aspects and biological significance. Mutat Res. 635:105–117. 2007. View Article : Google Scholar : PubMed/NCBI
37	Sherwood JL, Corcoran C, Brown H, Sharpe AD, Musilova M and Kohlmann A: Optimised pre-analytical methods improve KRAS mutation detection in circulating tumour DNA (ctDNA) from patients with non-small cell lung cancer (NSCLC). PLoS One. 11:e01501972016. View Article : Google Scholar : PubMed/NCBI
38	Stankovic T, Milinkovic V, Bankovic J, Dinic J and Tanic N, Dramicanin T and Tanic N: Comparative analyses of individual and multiple alterations of p53, PTEN and p16 in non-small cell lung carcinoma, glioma and breast carcinoma samples. Biomed Pharmacother. 68:521–526. 2014. View Article : Google Scholar : PubMed/NCBI
39	Stjernström A, Karlsson C, Fernandez OJ, Söderkvist P, Karlsson MG and Thunell LK: Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung. Cancer Med. 3:337–348. 2014. View Article : Google Scholar : PubMed/NCBI
40	Ylikorkala A, Avizienyte E, Tomlinson IP, Tiainen M, Roth S, Loukola A, Hemminki A, Johansson M, Sistonen P, Markie D, et al: Mutations and impaired function of LKB1 in familial and non-familial Peutz-Jeghers syndrome and a sporadic testicular cancer. Hum Mol Genet. 8:45–51. 1999. View Article : Google Scholar : PubMed/NCBI
41	Pécuchet N, Laurent-Puig P, Mansuet-Lupo A, Legras A, Alifano M, Pallier K, Didelot A, Gibault L, Danel C, Just PA, et al: Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer. Oncotarget. Nov 25–2015.(Epub ahead of print). PubMed/NCBI